Clinical trials: Irritation
Fragile X Syndrome
Biomarker and DNA Collection in Subjects Participating in Protocol 22003
The subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22003 will be offered participation in 22003A which will evaluate secreted protein before and after treatment with STX209 and…
- Trial name
- NCT00892580
- Testing
- STX209
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Seaside Therapeutics, Inc.
Irritable Bowel Syndrome
Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)
The purpose of this study is to compare the effectiveness of 2 IBS treatment strategies: Strategy A = MeteoSpasmyl®, on-demand therapy Strategy B = standard of care chosen by the physician
- Trial name
- NCT01404923
- Testing
- anti spasmodic agents, alverine citrate, simeticone
- Volunteers
- 436 people
- Sponsor
- Laboratoires Mayoly Spindler
Hygiene
Dermacyd Femina (Lactic Acid) Pocket BR - Photo Evaluation
To demonstrate the absence of photoirritation and photosensitization potential of the product Dermacyd Femina (Lactic Acid) Pocket BR.
- Trial name
- NCT00783640
- Testing
- Lactic Acid
- Where
- Brazil
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Sanofi
Skin Irritability, Skin Sensitisation
Safety Dermatological Assessment of Topical Use Product Through Dressings Predictive Studies for Evaluation of Photoirritation and Dermal Photosensitivity
The purpose of this study is to prove the product tested does not cause photoirritation or photosensitization reactions when exposed to sun light.
- Trial name
- SAF DER ASSESS (NCT03015103)
- Testing
- Intimate Lubrificant Gel
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Kley Hertz S/A
Diarrhea-predominant Irritable Bowel Syndrome
Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D
The objective of this study is to evaluate the safety and efficacy Rifamycin SV-MMX® 600 mg tablets for patients with diarrhoea-predominant irritable bowel syndrome when administered two to three times daily.
- Trial name
- NCT03099785
- Testing
- Rifamycin SV 600mg t.i.d.
- Where
- 29 sites in Belgium, Germany and 2 more
- Volunteers
- 279 people
- Sponsor
- Cosmo Technologies Ltd
Irritable Bowel Syndrome, Vaginal Health
A Single Group Study to Evaluate the Effects of a Vaginal Probiotic on Vaginal and Digestive Health
This is a virtual single-group study that will last 12 weeks. Participants will take 1 capsule every day, with water. Questionnaires will be completed at baseline, 2 weeks, 4 weeks, and 12 weeks.
- Trial name
- NCT06124313
- Testing
- Vaginal Probiotic
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Rael
Irritable Colon, Irritable Bowel Syndrome (IBS)
Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers
This is a three-period crossover study to compare GW876008 and placebo to see if GW876008 will normalise blood flow responses after different emotional stimuli.
- Trial name
- NCT00376896
- Testing
- GW876008 200mcg, GW876008 20mcg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaginal Odor
The Effects of an Orally-Administered Probiotic on Vaginal Symptoms
This randomized, double-blind, placebo-controlled, virtual trial is designed to determine the efficacy of an orally-administered probiotic on alleviating vaginal odor and other vaginal symptoms.
- Trial name
- NCT07829861
- Testing
- Orally-administered probiotic
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Bonafide Health